In the early stage of cancer development, most patients do not show any clinical signs or symptoms, and since its discovery in 1981, CA125 has been used as a gold standard biomarker of epithelial ovarian cancer [157]. The gene discussed is MUC16; the disease is ovarian carcinoma.